DGAP-News: MagForce AG

MagForce AG to participate in seven upcoming international conferences in H2/2017

Berlin, Germany and Nevada, USA, September 05, 2017 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced its participation in seven upcoming scientific and investor conferences in the second half of 2017:

• Goldman Sachs Fourteenth Annual European Medtech and Healthcare Services Conference 2017
  Date: September 6-7, 2017
  Location: London, UK
  Presentation: Ben J. Lipps, CEO of MagForce AG, Thursday, September 7, 2017; 16:00 BST
   
• Berenberg & Goldman Sachs Sixth German Corporate Conference 2017
  Date: September 18-20, 2017
  Location: Munich, Germany
  Presentation: Ben J. Lipps, CEO of MagForce AG, Tuesday, September 19, 2017; 11:00 CET
   
• 17th European Congress of Neurosurgery (EANS2017)
  Date: October 1-5, 2017
  Location: Venice, Italy
  Booth: L, level: first floor
   
• International Brain Tumor Alliance (IBTA) Patient's Advocate Conference
  Date: October 19-22, 2017
  Location: London, UK
   
• MEDICA 2017
  Date: November 13-16, 2017
  Location: Düsseldorf, Germany
  Community booth: Berlin Partner für Wirtschaft und Technologie GmbH No. 15F42, hall 15
   
• 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO)
  Date: November 16-19, 2017
  Location: San Francisco, California, USA
  Booth: Golden Gate foyer , level: B1
  Presentation: EXPERIMENTAL THERAPEUTICS AND TUMOR MODELS,
  "Combined intracavitary thermotherapy with iron-oxide nanoparticles and radiotherapy as a promising treatment modality in recurrent GBM" (SURG-32)
  Presenter: Team of Prof. Dr. med. Walter Stummer, Director of the Clinic for Neurosurgery, University Hospital Münster
  Speaker: PD Dr. Dr. med. Oliver Grauer, Head of Neuro-Oncology Team, University Hospital Münster
  Date of presentation: Session 2C, Friday, November 17, 2017, 13:45 PDT
   
• German Equity Forum 2017
  Date: November 27-29, 2017
  Location: Frankfurt, Germany
  Presentation: Ben J. Lipps, CEO of MagForce AG, Tuesday, September 28, 2017; 16:30 CET
  Room: Oslo
   

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm^(R) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.

NanoTherm^(R), NanoPlan^(R), and NanoActivator^(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

For more information, please visit: www.magforce.com
Get to know our Technology: video (You Tube)
Stay informed and subscribe to our mailing list

Disclaimer
This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.